Clinical and Technical considerations for implementing PET brain imaging for dementia.
The number of cases of dementia has dramatically increased over the last decade. Imaging the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia has vastly improved. In recent years, the United States Food and Drug Administration (FDA) has approved three PET radiopharmaceuticals for detecting amyloid in brain and Tau PET radiopharmaceuticals are being investigated for the use of dementia imaging in clinical trials. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.